What is Novavax's SG&A?

Novavax (NVAX) reported SG&A of $28.78M in Q1 2026.

How has Novavax's SG&A changed year-over-year?

Novavax's SG&A decreased by 40.2% year-over-year, from $48.09M to $28.78M.

What is the long-term trend for Novavax's SG&A?

Over 2 years (2022 to 2025), Novavax's SG&A has grown at a -43.2% compound annual growth rate (CAGR), from $488.69M to $157.48M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Novavax NVAX SG&A

SG&A at other companies

Merck & Co.MRK

$2.7B+5.8%

Viridian Therapeutics, Inc.VRDN

$38.68M+126%

ALN

Alnylam PharmaceuticalsALNY

$322.55M+34.4%

Gilead SciencesGILD

$1.45B+15.3%

BioCryst PharmaceuticalsBCRX

$94.55M+14.7%

ImmunityBio, Inc.IBRX

——

Segments

By segment

See full

Reportable Segment$28.78M-40.2%

Other financials

Income statement

See full

Revenue$139.5M-79.1%

Gross profit$108.8M-83.3%

Operating income-$15.4M-103%

Net income-$9.5M-102%

EPS (diluted)-$0.06-102%

Balance sheet

See full

Cash & equivalents$228.4M-13.3%

Total debt$295.1M+404%

Total equity-$144.8M-91.4%

Total assets$1.0B-19.3%

Cash flow

See full

Operating cash flow-$32.4M+82.5%

CapEx$1.3M-20.4%

Free cash flow-$33.7M+82.0%

Valuation

See full

Market cap$1.46B+41.0%

Enterprise value$1.53B+83.6%

P/S2.5×+1.6×

Profitability

See full

Gross margin85%-2.5pp

Operating margin-13.1%-45.9pp

Net margin-14.7%-52.9pp

FCF margin-58.9%-61.4pp

Returns & leverage

See full

Return on equity-238.6%—

Debt / equity1.5×—

Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Novavax's SG&A?: Novavax (NVAX) reported SG&A of $28.78M in Q1 2026.
How has Novavax's SG&A changed year-over-year?: Novavax's SG&A decreased by 40.2% year-over-year, from $48.09M to $28.78M.
What is the long-term trend for Novavax's SG&A?: Over 2 years (2022 to 2025), Novavax's SG&A has grown at a -43.2% compound annual growth rate (CAGR), from $488.69M to $157.48M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.